Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the middle of the week is here. After all, this means just a few days are left until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we will keep busy brewing another cup of stimulation — mocha nut fudge is our choice today, for no particular reason — and forage for interesting items. Meanwhile, here are some tidbits to get you going. Have a splendid day and we hope you conquer the world. …

Four lawmakers from the Senate and House introduced a bill to prohibit illegal marketing and distribution of opioids; create criminal liability for top company executives; penalize drug makers who illegally advertise, market or distribute an opioid product; and require drug makers to reimburse the country for the negative economic impact of their products. The move comes after former Insys Therapeutics (INSY) executives were convicted of bribing doctors to prescribe an addictive opioid and Rochester Distributor executives were indicted for failing to monitor opioid shipments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • No, this is not my blog, but may I take issue with this wording in the Novartis piece? “The drug may cost up to $5 million.”
    Uh, no – it can’t “cost” anything like that, as it implies a link to the actual production of same. The ‘usurious charge by NVS may be up to 5 Million USD’ but that will NOT be their cost.”

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy